Last reviewed · How we verify
NCT07160491: EARLY-OPEN
Early Thrombolysis Guided by AI-Assisted App in Patients With STEMI
NA trial testing A novel artificial intelligence assisted mobile application in STEMI - ST Elevation Myocardial Infarction in 3,356 participants. Currently enrolling.
31 July 2029
Quick facts
| Lead sponsor | Shenyang Northern Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3,356 |
| Start date | 8 September 2025 |
| Primary completion | 31 July 2029 |
| Estimated completion | 31 July 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- A novel artificial intelligence assisted mobile application
Conditions studied
- STEMI - ST Elevation Myocardial Infarction — all drugs for STEMI - ST Elevation Myocardial Infarction →
Sponsor
Shenyang Northern Hospital
Who can join
Adults 18 to 80, any sex, with STEMI - ST Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to elucidate whether guiding by a novel artificial intelligence assisted mobile application can improve the clinical outcomes of patients in whom "guide wire passing through the lesion" could not be achieved within 120 min after diagnosis of STEMI, compared to conventional treatment strategies. With concerns of the inadequate use of thrombolysis in patients with STEMI in China, this study applies a new artificial intelligence assisted mobile application to guide the process of thrombolysis combined with PCI treatment, in order to accomplish the rapid coordination and cooperation of the whole medical network during re-perfusion treatment in different regions and different medical institutions in China, increases the proportion of early thrombolysis in pre-hospital setting, shortens the time from STEMI onset to reperfusion, and provides a reliable, effective and replicable new strategy for promoting and optimizing early reperfusion.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07160491
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for STEMI - ST Elevation Myocardial Infarction
Currently open trials in the same condition.
- NCT06013020 — Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus · Phase 4 · recruiting
- NCT06384846 — AI Algorithms in Prediction of ACS Based on Leukocyte Properties · recruiting
- NCT04436978 — What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? · Phase 4 · recruiting
- NCT05800951 — Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock · active not recruiting
- NCT05347732 — Predictors of Failed Thrombolysis in Acute Myocardial Infarction · recruiting
Other Shenyang Northern Hospital trials
Trials by the same sponsor.
- NCT07445360 — Circumferential Pulmonary Venous Isolation Combined With Bachmann Bundle Modification Versus Circumferential Pulmonary V · NA · not yet recruiting
- NCT07374718 — Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate- · NA · not yet recruiting
- NCT07351643 — CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF · Phase 4 · not yet recruiting
- NCT07362966 — Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant · Phase 4 · not yet recruiting
- NCT07383155 — Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07160491 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenyang Northern Hospital
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07160491.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing